In the present study, we first demonstrated that CPNE1 interacts with RACK1 to further activate the MET signaling pathway and proposed a novel combination treatment strategy with MET and EGFR inhibitors in NSCLC (Fig. 8E). Here, RACK1 is linked to non-small cell lung carcinoma.